Immunotherapy: Incorporation in the evolving paradigm of renal cancer management and future prospects

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Significant progress has been made in the management of renal cell carcinoma (RCC) during the last few decades. In early stage, localized disease, surgical resection remains the modality of choice, with no therapeutic interventions as options for post-operative therapy other than simple observation and clinical surveillance. However, treatment options in the advanced or metastatic setting are increasing at a dizzying pace, initially with cytokine therapy, then with the increased availability of targeted therapy including novel small-molecule inhibitors of receptor tyrosine kinases and monoclonal antibodies targeting novel proteins, establishing them as the current standard of care. Even more recently, immunotherapy has seen tremendous development in the form of immune checkpoint inhibition and vaccines. Overall, these interventions have gradually changed the landscape of cancer management in general, and metastatic renal cell carcinoma (mRCC) in particular. This is exemplified by the recent United States Food and Drug Administration (USFDA) approval of nivolumab for patients with mRCC after failure of TKI therapy. In this review, we present a brief overview of the current management of mRCC, primarily the clear cell subtype (ccRCC), and discuss the major clinical trials and data on the immunotherapy in advanced or mRCC.

Original languageEnglish (US)
Pages (from-to)17313-17327
Number of pages15
JournalOncotarget
Volume8
Issue number10
DOIs
StatePublished - 2017

Fingerprint

Kidney Neoplasms
Immunotherapy
Renal Cell Carcinoma
Therapeutics
Drug Approval
Receptor Protein-Tyrosine Kinases
Protein Transport
United States Food and Drug Administration
Standard of Care
Vaccines
Monoclonal Antibodies
Observation
Clinical Trials
Cytokines
Neoplasms

Keywords

  • Checkpoint Inhibition
  • Cytokines
  • Immunotherapy
  • Renal cell carcinoma
  • Vaccines

ASJC Scopus subject areas

  • Oncology

Cite this

Immunotherapy : Incorporation in the evolving paradigm of renal cancer management and future prospects. / Liu, Kenneth G.; Gupta, Sorab; Goel, Sanjay.

In: Oncotarget, Vol. 8, No. 10, 2017, p. 17313-17327.

Research output: Contribution to journalReview article

@article{d8930fa692f548c6a466fcd63106d815,
title = "Immunotherapy: Incorporation in the evolving paradigm of renal cancer management and future prospects",
abstract = "Significant progress has been made in the management of renal cell carcinoma (RCC) during the last few decades. In early stage, localized disease, surgical resection remains the modality of choice, with no therapeutic interventions as options for post-operative therapy other than simple observation and clinical surveillance. However, treatment options in the advanced or metastatic setting are increasing at a dizzying pace, initially with cytokine therapy, then with the increased availability of targeted therapy including novel small-molecule inhibitors of receptor tyrosine kinases and monoclonal antibodies targeting novel proteins, establishing them as the current standard of care. Even more recently, immunotherapy has seen tremendous development in the form of immune checkpoint inhibition and vaccines. Overall, these interventions have gradually changed the landscape of cancer management in general, and metastatic renal cell carcinoma (mRCC) in particular. This is exemplified by the recent United States Food and Drug Administration (USFDA) approval of nivolumab for patients with mRCC after failure of TKI therapy. In this review, we present a brief overview of the current management of mRCC, primarily the clear cell subtype (ccRCC), and discuss the major clinical trials and data on the immunotherapy in advanced or mRCC.",
keywords = "Checkpoint Inhibition, Cytokines, Immunotherapy, Renal cell carcinoma, Vaccines",
author = "Liu, {Kenneth G.} and Sorab Gupta and Sanjay Goel",
year = "2017",
doi = "10.18632/oncotarget.14388",
language = "English (US)",
volume = "8",
pages = "17313--17327",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "10",

}

TY - JOUR

T1 - Immunotherapy

T2 - Incorporation in the evolving paradigm of renal cancer management and future prospects

AU - Liu, Kenneth G.

AU - Gupta, Sorab

AU - Goel, Sanjay

PY - 2017

Y1 - 2017

N2 - Significant progress has been made in the management of renal cell carcinoma (RCC) during the last few decades. In early stage, localized disease, surgical resection remains the modality of choice, with no therapeutic interventions as options for post-operative therapy other than simple observation and clinical surveillance. However, treatment options in the advanced or metastatic setting are increasing at a dizzying pace, initially with cytokine therapy, then with the increased availability of targeted therapy including novel small-molecule inhibitors of receptor tyrosine kinases and monoclonal antibodies targeting novel proteins, establishing them as the current standard of care. Even more recently, immunotherapy has seen tremendous development in the form of immune checkpoint inhibition and vaccines. Overall, these interventions have gradually changed the landscape of cancer management in general, and metastatic renal cell carcinoma (mRCC) in particular. This is exemplified by the recent United States Food and Drug Administration (USFDA) approval of nivolumab for patients with mRCC after failure of TKI therapy. In this review, we present a brief overview of the current management of mRCC, primarily the clear cell subtype (ccRCC), and discuss the major clinical trials and data on the immunotherapy in advanced or mRCC.

AB - Significant progress has been made in the management of renal cell carcinoma (RCC) during the last few decades. In early stage, localized disease, surgical resection remains the modality of choice, with no therapeutic interventions as options for post-operative therapy other than simple observation and clinical surveillance. However, treatment options in the advanced or metastatic setting are increasing at a dizzying pace, initially with cytokine therapy, then with the increased availability of targeted therapy including novel small-molecule inhibitors of receptor tyrosine kinases and monoclonal antibodies targeting novel proteins, establishing them as the current standard of care. Even more recently, immunotherapy has seen tremendous development in the form of immune checkpoint inhibition and vaccines. Overall, these interventions have gradually changed the landscape of cancer management in general, and metastatic renal cell carcinoma (mRCC) in particular. This is exemplified by the recent United States Food and Drug Administration (USFDA) approval of nivolumab for patients with mRCC after failure of TKI therapy. In this review, we present a brief overview of the current management of mRCC, primarily the clear cell subtype (ccRCC), and discuss the major clinical trials and data on the immunotherapy in advanced or mRCC.

KW - Checkpoint Inhibition

KW - Cytokines

KW - Immunotherapy

KW - Renal cell carcinoma

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85014687534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014687534&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14388

DO - 10.18632/oncotarget.14388

M3 - Review article

C2 - 28061473

AN - SCOPUS:85014687534

VL - 8

SP - 17313

EP - 17327

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 10

ER -